Contribution of hypervariable domains to the conformation of a broadly neutralizing glycoprotein 120 epitope. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Contribution of hypervariable domains to the conformation of a broadly neutralizing glycoprotein 120 epitope.

AIDS Res Hum Retroviruses. 1995 Jul;11(7):777-81. Unique Identifier : AIDSLINE MED/96053839
Lee CN; Robinson J; Mazzara G; Cheng YL; Essex M; Lee TH; Department of Cancer Biology, Harvard School of Public Health,; Boston, Massachusetts 02115, USA.

Abstract: Three of the five hypervariable domains (V1-V3) of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 have previously been shown to be dispensable for antigenic epitopes recognized by broadly neutralizing monoclonal antibodies. In this study, the influence of the V4 and V5 domains on an epitope recognized by a broadly neutralizing human monoclonal antibody, 1.5e, was investigated. In contrast with the V1, V2, and V3 domains of gp120, the V4 and V5 domains were found to be critical for binding to both CD4 and 1.5e. Our results suggest that V4 and V5 are in structurally less flexible regions of gp120 than V1, V2, and V3 and raises the question of whether variable domains V4 and V5 are also indispensable for other broadly neutralizing antibodies in the same class as 1.5e.
Keywords: Antibodies, Monoclonal Antigens, CD/IMMUNOLOGY Antigens, CD4/IMMUNOLOGY Base Sequence Binding Sites, Antibody Epitopes/*CHEMISTRY Human HIV Envelope Protein gp120/*CHEMISTRY/*GENETICS/IMMUNOLOGY HIV-1/GENETICS/*IMMUNOLOGY Molecular Sequence Data Mutagenesis, Site-Directed Neutralization Tests Oligodeoxyribonucleotides *Protein Conformation Recombinant Proteins/CHEMISTRY/IMMUNOLOGY Sequence Deletion Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S. *Variation (Genetics) JOURNAL ARTICLE

KWDantibodies,monoclonalantigens,cd/immunologyantigens,cd4/immunologybasesequencebindingsites,antibodyepitopes/KWDchemistryhumanhivenvelopeproteingp120/KWDchemistry/KWDgenetics/immunologyhiv-1/genetics/KWDimmunologymolecularsequencedatamutagenesis,site-directedneutralizationtestsoligodeoxyribonucleotidesKWDproteinconformationrecombinantproteins/chemistry/immunologysequencedeletionsupport,uKWDsKWDgov't,non-pKWDhKWDsKWDsupport,uKWDsKWDgov't,pKWDhKWDs
960130
M9610759

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .